BioVaxys
Etobicoke
About BioVaxys
BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $15.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: cnsx:BIOV
- Website: biovaxys.com
- Phone: 610 977 2440
Industries & Categories
Biopharma, Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/biovaxys-6477 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.